Knoop A, Andreasen P A, Andersen J A, Hansen S, Laenkholm A V, Simonsen A C, Andersen J, Overgaard J, Rose C
Department of Oncology, Odense University Hospital, Denmark.
Br J Cancer. 1998 Mar;77(6):932-40. doi: 10.1038/bjc.1998.154.
The uPA-mediated pathway of plasminogen activation is central to cancer metastasis. Whether uPA and PAI-1 are related to local recurrence, metastatic spread or both is not clear. We present a retrospective study of 429 primary breast cancer patients with a median follow-up of 5.1 years, in which the levels of uPA and PAI-1 in tumour extracts were analysed by means of an enzyme-linked immunosorbent assay. The median values of uPA and PAI-1, which were used as cut-off points, were 4.5 and 11.1 ng mg(-1) protein respectively. The levels of uPA and PAI-1 were correlated with tumour size, degree of anaplasia, steroid receptor status and number of positive nodes. Patients with high content of either uPA or PAI-1 had increased risk of relapse and death. We demonstrated an independent ability of PAI-1 to predict distant metastasis (relative risk 1.7, confidence limits 1.22 and 2.46) and that neither uPA nor PAI-1 provided any information regarding local recurrence.
尿激酶型纤溶酶原激活物（uPA）介导的纤溶酶原激活途径在癌症转移中起核心作用。uPA和纤溶酶原激活物抑制剂-1（PAI-1）是否与局部复发、转移扩散或两者均有关尚不清楚。我们对429例原发性乳腺癌患者进行了一项回顾性研究，中位随访时间为5.1年，采用酶联免疫吸附测定法分析肿瘤提取物中uPA和PAI-1的水平。用作截断点的uPA和PAI-1的中位值分别为4.5和11.1 ng mg⁻¹蛋白。uPA和PAI-1的水平与肿瘤大小、间变程度、类固醇受体状态及阳性淋巴结数目相关。uPA或PAI-1含量高的患者复发和死亡风险增加。我们证实PAI-1具有独立预测远处转移的能力（相对风险1.7，置信区间1.22和2.46），且uPA和PAI-1均未提供有关局部复发的任何信息。
